搜尋結果
2024年5月16日 · Trivalent subunit vaccines, unadjusted Agrippal S1 (group I) and immunoadjuvant Grippol Plus (group II), containing 5 μg of actual influenza virus strains, were administered respectively to 37 and 42 women in the second and third trimester of physiological
4 天前 · Influenza vaccine. Influenza vaccines, colloquially known as flu shots, are vaccines that protect against infection by influenza viruses. [12] [13] New versions of the vaccines are developed twice a year, as the influenza virus rapidly changes. [12] While their effectiveness varies from year to year, most provide modest to high protection ...
- Afluria, Fluarix, Fluzone, others
- Influenza virus
- inactivated, attenuated, recombinant
2024年5月1日 · This study assesses immunogenicity and safety of NBP607-QIV to Agrippal which are indicated for active immunization for the prevention of influenza disease. Total of 675 subjects or above (450 subjects for NBP607-QIV arm and 225 subjects for Agrippal arm) of 6 to 35 months of age are enrolled, and each subject is administered with ...
2024年5月5日 · AGRIPPAL™ S1. Suspension for injection in pre-filled syringe. Influenza Vaccine, Surface Antigen, Inactivated. 2011-2012 NH Season. Presentation: Clear, colourless, sterile liquid for injection. Composition. Each dosage (0.5 ml) contains: Influenza virus surface antigen (haemagglutinin and neuraminidase),
2024年5月1日 · A Phase II, Open Label, Uncontrolled, Multi Center Study to Evaluate Safety and Immunogenicity of AGRIPPAL S1 Surface Antigen, Inactivated, Influenza Vaccine, Formulation 2006-2007, when Administered to Non-Elderly Adult and Elderly Subjects - ND. 开始日期 2006-05-21. 申办/合作机构. Chiron Corp.
2024年5月2日 · A Phase II, Open Label, Uncontrolled, Multi Center Study to Evaluate Safety and Immunogenicity of AGRIPPAL S1 Surface Antigen, Inactivated, Influenza Vaccine, Formulation 2006-2007, when Administered to Non-Elderly Adult and Elderly Subjects - ND
2024年5月16日 · 概要. 基本信息. 药物类型. 疫苗. 别名. IC31 Flu vaccine CSL/Valneva、Seasonal trivalent influenza vaccine (Agrippal + IC31) CSL/Valneva. 靶点. TLR9. 作用机制. TLR9激动剂 (Toll样受体9激动剂)、免疫刺激剂. 治疗领域. 感染 呼吸系统疾病. 在研适应症 - 非在研适应症. 流感病毒感染. 原研机构. Novartis AG Intercell AG. 在研机构 - 非在研机构. Valneva SE CSL Ltd. 最高研发阶段 无进展 临床1期. 首次获批日期 - 最高研发阶段 (中国) - 特殊审评 - 关联.
